NCT03662334 - A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2013

Primary Completion Date

February 27, 2014

Study Completion Date

February 27, 2014

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

Rapid Acting insulin with pre-treatment of rHuPH20

Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.

DEVICE

Sham injection

A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.

Trial Locations (1)

91911

Profil Institute for Clinical Research, Chula Vista